Tag:
Vertex Pharmaceuticals
Latest Headlines
Latest Headlines
Astellas, Lilly grab social-media limelight
Social media buzz can be both good and bad, and smart companies want to keep track of both.
Vertex chief's pay dropped to $13.4M last year
Outgoing Vertex Pharmaceuticals CEO Matthew Emmens saw his 2011 compensation drop slightly, despite the company's successful launch of its new hepatitis C drug, Incivek.
Merck says Victrelis can interfere with HIV meds
Merck ( $MRK ) has notified doctors that its new hepatitis C drug Victrelis interferes with commonly used AIDS drugs. Victrelis can reduce the effectiveness of the HIV-fighters--and vice-versa--Merck...
One father's heartbreak inspired a $250M quest for a cure
How one father's loss turned into gain for cystic fibrosis patients and Vertex Pharmaceuticals ( $VRTX ): After the death of his son, Boston businessman Joe O'Donnell spent years raising $250 million
How do the 12 priciest drugs in the U.S. stack up?
Last week, Vertex Pharmaceuticals ( $VRTX ) got FDA approval for Kalydeco, the first cystic fibrosis drug to address the disease's cause, rather than just its symptoms. The price tag: $294,000. But as
Botox delivers for Allergan, Dr. Reddy's sees big profit increase during quarter
Another day, another round of earnings calls. Today's roundup includes Allergan, which received a boost from Botox, a widely known wrinkle-fighter that is now garnering approvals around the world for
Vertex backs up pricey new CF drug with co-pay help
Vertex Pharmaceuticals ( $VRTX ) achieved another major milestone with FDA's approval of its cystic fibrosis therapy Kalydeco. The "breakthrough" product is the first to address CF's...
Interview: Vertex CEO worries about 'hyper-focus' on hep C
No question that Vertex Pharmaceuticals ( $VRTX ) needs another hit to follow its new hepatitis C drug Incivek. But that's just one of the things on the to-do list for incoming CEO Jeffrey Leiden, who
Vertex's new leader expected to diversify
Vertex Pharmaceuticals ( $VRTX ) will be getting its second new leader in two years as it seeks to become a more diversified drug company. Former Abbott Laboratories executive Jeffrey Leiden will
Hep C smackdown: Vertex at $420M, Merck at $31M
It's convenient for hepatitis C market-watchers that Vertex Pharmaceuticals ($VRTX) and Merck ($MRK) reported their earnings less than 24 hours apart. There's no need to speculate about how the two
